IL318036A - Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis - Google Patents

Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis

Info

Publication number
IL318036A
IL318036A IL318036A IL31803624A IL318036A IL 318036 A IL318036 A IL 318036A IL 318036 A IL318036 A IL 318036A IL 31803624 A IL31803624 A IL 31803624A IL 318036 A IL318036 A IL 318036A
Authority
IL
Israel
Prior art keywords
pcrv
psl
bronchiectasis
treatment
bispecific antibodies
Prior art date
Application number
IL318036A
Other languages
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL318036A publication Critical patent/IL318036A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL318036A 2022-06-29 2023-06-28 Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis IL318036A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263367309P 2022-06-29 2022-06-29
PCT/EP2023/067575 WO2024003103A1 (en) 2022-06-29 2023-06-28 Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis

Publications (1)

Publication Number Publication Date
IL318036A true IL318036A (en) 2025-02-01

Family

ID=87155664

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318036A IL318036A (en) 2022-06-29 2023-06-28 Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis

Country Status (11)

Country Link
US (1) US20250382356A1 (en)
EP (1) EP4547712A1 (en)
JP (1) JP2025521777A (en)
KR (1) KR20250044668A (en)
CN (1) CN119546631A (en)
AU (1) AU2023300231A1 (en)
CA (1) CA3260770A1 (en)
IL (1) IL318036A (en)
MA (1) MA71321A (en)
TW (1) TW202417478A (en)
WO (1) WO2024003103A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025231041A1 (en) * 2024-04-30 2025-11-06 Renovion, Inc. Methods for reducing symptoms in subjects suffering from bronchiectasis and other pulmonary diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
WO2013070615A1 (en) 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
US20150284450A1 (en) 2012-11-06 2015-10-08 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
US20170183397A1 (en) 2014-05-05 2017-06-29 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
HK1257193A1 (en) * 2015-11-30 2019-10-18 Medimmune Limited Method for preventing or treating nosocomial pneumonia

Also Published As

Publication number Publication date
CA3260770A1 (en) 2024-01-04
MA71321A (en) 2025-04-30
AU2023300231A1 (en) 2025-02-13
KR20250044668A (en) 2025-04-01
US20250382356A1 (en) 2025-12-18
WO2024003103A1 (en) 2024-01-04
EP4547712A1 (en) 2025-05-07
CN119546631A (en) 2025-02-28
JP2025521777A (en) 2025-07-10
TW202417478A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
IL316615A (en) Bispecific antibodies and methods of treating ocular disease
GB202218173D0 (en) Methods and apparatuses for internet of things
IL316368A (en) Anti-tl1a antibodies and methods of use thereof
IL315887A (en) Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
IL314211A (en) Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
IL319674A (en) Humanized anti-il-1r3 antibody and methods of use
IL319590A (en) Multispecific antibodies and methods of use thereof
IL286337A (en) Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
IL315845A (en) Anti-dectin-1 antibodies and methods of use thereof
CA3260770A1 (en) Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis
IL318694A (en) Anti-ccr8 antibodies and methods of use
IL317690A (en) Anti-gpnmb antibodies and methods of use thereof
IL313864A (en) Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
IL311003A (en) Anti-her2 antibodies and methods of use thereof
CA3267318A1 (en) Antibodies, compositions, and methods of treatment
IL316700A (en) Anti-bmp9 antibodies and methods of use thereof
IL325837A (en) Bispecific PD-L1X4-1BB antibodies and methods of using them
IL325840A (en) Bispecific PD-L1XCD28 antibodies and methods of using them
GB202205715D0 (en) Treatment of neutrophilic dermatoses
GB202408901D0 (en) Antibodies and methods of treatment
HK40091622A (en) Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
CA3297963A1 (en) Bispecific pd-l1x4-1bb antibodies and methods of use thereof
CA3297983A1 (en) Bispecific pd-l1xcd28 antibodies and methods of use thereof
GB202502639D0 (en) Antibodies for treatment of diseases
GB202502640D0 (en) Antibodies for treatment of diseases